Relationship of cystatin C with coronary artery disease and its severity

被引:104
作者
Doganer, Yusuf C. [1 ]
Aydogan, Umit [2 ]
Aydogdu, Aydogan [3 ]
Aparci, Mustafa [8 ]
Akbulut, Halil [2 ]
Nerkiz, Polat [2 ]
Turker, Turker [4 ]
Cayci, Tuncer [5 ]
Barcin, Cem [6 ]
Saglam, Kenan [7 ]
机构
[1] Gulhane Mil Med Acad, Turkish Mil Acad Primary Care Ctr, Dept Family Med, Ankara, Turkey
[2] Gulhane Mil Med Acad, Dept Family Med, Ankara, Turkey
[3] Gulhane Mil Med Acad, Dept Endocrinol, Ankara, Turkey
[4] Gulhane Mil Med Acad, Dept Epidemiol, Ankara, Turkey
[5] Gulhane Mil Med Acad, Dept Biochem, Ankara, Turkey
[6] Gulhane Mil Med Acad, Dept Cardiol, Ankara, Turkey
[7] Gulhane Mil Med Acad, Dept Internal Med, Ankara, Turkey
[8] Etimesgut Mil Hosp, Dept Cardiol, TR-06790 Ankara, Turkey
关键词
atherosclerosis; coronary angiography; coronary artery disease; cystatin C; HEART-DISEASE; CATHEPSIN-S; ATHEROSCLEROSIS; PROGRESSION; INFLAMMATION; DEFICIENCY; EXPRESSION;
D O I
10.1097/MCA.0b013e32835b6761
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Cystatin C, which is an endogenous marker for renal function, is reported to be a novel marker for coronary atherosclerosis. In this study, we aimed to evaluate its role in determining the presence and also the severity of coronary atherosclerosis in patients with coronary artery disease (CAD). Materials and methods Eighty-eight patients who underwent elective coronary angiography were enrolled in the study. Patients with heart failure, renal failure, diabetes, and thyroid disease were excluded from the study. The study population was divided into three groups: individuals with normal coronary arteries, patients with critical CAD, and patients with noncritical CAD. We also analyzed the relationship of cystatin C levels with the presence and the severity of CAD and the number of vessels involved. Results The mean age of the study group was 51.73 +/- 9.21 years, and the majority were men (n= 71, 80.7%). Cystatin C levels were significantly lower in patients with CAD (1334.86 +/- 93.45 vs. 836.49 +/- 411.29, P < 0.001). It was significantly lower in patients with critical CAD compared with those with noncritical CAD and normal individuals (656.60 +/- 346.35, 1016.38 +/- 396.54, and 1334.86 +/- 393.45, P < 0.001, respectively). Serum levels of cystatin C according to the numbers of coronary vessels such as none, single-vessel, two-vessel, three-vessel, and four-vessel disease were as follows: 1334.86 +/- 393.45, 801.67 +/- 418.70, 993.90 +/- 457.34, 744.09 +/- 354.53, and 682.30 +/- 294.43, respectively. Conclusion Lower cystatin C levels may be associated with increased severity of CAD in clinically stable patients, whereas higher levels may indicate the presence of any vulnerable plaque. It may also guide the diagnostic and therapeutic options for the clinical scene on the presentation. Coron Artery Dis 24: 119-126 (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 30 条
[1]   Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms [J].
Abisi, S. ;
Burnand, K. G. ;
Humphries, J. ;
Waltham, M. ;
Taylor, P. ;
Smith, A. .
BRITISH JOURNAL OF SURGERY, 2008, 95 (03) :333-337
[2]  
Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161
[3]   Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice [J].
Bengtsson, E ;
To, F ;
Håkansson, K ;
Grubb, A ;
Brånén, L ;
Nilsson, J ;
Jovinge, S .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (10) :2151-2156
[4]  
Bengtsson E, 2005, ATHEROSCLEROSIS, V180, P45, DOI [10.1016/j.atherosclerosis.2004.12.025, 10.1016/j.athersclerosis.2004.12.025]
[5]   Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease [J].
Eriksson, P ;
Deguchi, H ;
Samnegård, A ;
Lundman, P ;
Boquist, S ;
Tornvall, P ;
Ericsson, CG ;
Bergstrand, L ;
Hansson, LO ;
Ye, S ;
Hamsten, A .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (03) :551-557
[6]   Association between serum cystatin C, monocytes and other inflammatory markers [J].
Evangelopoulos, A. A. ;
Vallianou, N. G. ;
Bountziouka, V. ;
Katsagoni, C. ;
Bathrellou, E. ;
Vogiatzakis, E. D. ;
Bonou, M. S. ;
Barbetseas, J. ;
Avgerinos, P. C. ;
Panagiotakos, D. B. .
INTERNAL MEDICINE JOURNAL, 2012, 42 (05) :517-522
[7]   Cystatin C as a marker of GFR -: history, indications, and future research [J].
Filler, G ;
Bökenkamp, A ;
Hofmann, W ;
Le Bricon, T ;
Martínez-Brú, C ;
Grubb, A .
CLINICAL BIOCHEMISTRY, 2005, 38 (01) :1-8
[8]   Clinical Prognostic Significance of Plasma Cystatin C Levels among Patients With Acute Coronary Syndrome [J].
Ge, Changjiang ;
Ren, Fang ;
Lu, Shuzheng ;
Ji, Fengqing ;
Chen, Xin ;
Wu, Xiaofan .
CLINICAL CARDIOLOGY, 2009, 32 (11) :644-648
[9]   Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J].
Go, AS ;
Chertow, GM ;
Fan, DJ ;
McCulloch, CE ;
Hsu, CY .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) :1296-1305
[10]   Elastin- and collagen-rich human carotid plaques have increased levels of the cysteine protease inhibitor cystatin C [J].
Goncalves, Isabel ;
Ares, Mikko P. S. ;
Moberg, Anna ;
Moses, Jonatan ;
To, Fong ;
Montan, Jonathan ;
Pedro, Luis M. ;
Dias, Nuno ;
Fernandes e Fernandes, Jose ;
Fredrikson, Gunilla Nordin ;
Nilsson, Jan ;
Jovinge, Stefan ;
Bengtsson, Eva .
JOURNAL OF VASCULAR RESEARCH, 2008, 45 (05) :395-401